Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Market Cap	25.63B
Revenue (ttm)	27.43M
Net Income (ttm)	-356.15M
Shares Out	58.31M
EPS (ttm)	-6.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,288
Average Volume	402,826
Open	438.00
Previous Close	439.50
Day's Range	423.00 - 438.00
52-Week Range	78.30 - 505.00
Beta	n/a
RSI	61.01
Earnings Date	Nov 13, 2025

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen rece...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6949

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.